Cytochrome P450 2E1 and Iron Overload
Insulin Resistance, Iron Overload
About this trial
This is an interventional treatment trial for Insulin Resistance focused on measuring insulin resistance, iron overload, phlebotomy, hepatic iron overload
Eligibility Criteria
Inclusion Criteria: Male patients aged from 18 to 70 years Hepatic iron overload measured by magnetic resonance imaging [MRI] (> 36 µmol/g and < 200 µmol/L) Homozygosity for the C282Y mutation of the HFE or dysmetabolic iron overload syndrome (DIOS) based on the presence of at least one of these following metabolic abnormalities: Overweight: BMI > 25 kg/m2 Waist/hip circumference (cm) > 0.90 Diabetes mellitus (fasting blood glucose level >1.25g/L or blood glucose level after 2 hours > 2g/L) or glucose intolerance (fasting blood glucose level between 1.10 and 1.25g/L) Total cholesterolemia > 6.2 mmol/L or HDL-Cholesterol < 0.9 mmol/L TG>= 1.7 mmol Written informed consent Non-Inclusion Criteria: Consumption of alcohol > 50 g/day and of any CYP2E1 inhibitor substances Smoker > 5 cigarets/day History of blood donation or venesection Other causes of iron overload: aceruloplasminaemia, haematological disorder (abnormal blood counting), late cutaneous porphyria (cutaneous bullous disorders and photosensibilisation) , martial treatment, repeated transfusions. Inflammatory syndrome (CRP > 3ng/ml)
Sites / Locations
- CHU Nantes
- Unité d'Investigation Clinique - Hôpital Pontchaillou
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Venesection therapy
no venesection therapy